Research programme: synthetic natriuretic peptide - Capricor Therapeutics

Drug Profile

Research programme: synthetic natriuretic peptide - Capricor Therapeutics

Alternative Names: CU-NP

Latest Information Update: 23 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Capricor Therapeutics
  • Class Natriuretic peptides
  • Mechanism of Action Natriuretic peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Kidney disorders

Most Recent Events

  • 16 Feb 2017 Capricor Therapeutics has elected to terminate its license agreement with the Mayo Clinic for natriuretic peptide receptor agonists, including Cenderitide
  • 31 Dec 2013 Preclinical development is ongoing in USA
  • 21 Nov 2013 Nile Therapeutics has merged with Capricor to form Capricor Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top